Literature DB >> 10829059

Trastuzumab in CSF.

B C Pestalozzi, S Brignoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10829059     DOI： 10.1200/JCO.2000.18.11.2349

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  93 in total

1.  Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies.

Authors:  Javier Puente Vázquez; Sara López-Tarruella Cobo; José A García-Sáenz; Antonio Casado Herráez; Fernando Moreno Antón; Teresa Sampedro Gimeno; Coralia Bueno Muiño; Enrique Grande Pulido; Miguel Martín Jiménez; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

Review 2.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

Review 3.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

4.  Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients.

Authors:  Taher Abu Hejleh; Barry R Deyoung; Eric Engelman; Jeremy M Deutsch; Bridget Zimmerman; Thorvardur R Halfdanarson; Daniel J Berg; Kalpaj R Parekh; William R Lynch; Mark D Iannettoni; Sudershan Bhatia; Gerald Clamon
Journal:  World J Gastrointest Oncol       Date:  2012-05-15

Review 5.  Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?

Authors:  Eleonora Teplinsky; Francisco J Esteva
Journal:  Curr Oncol Rep       Date:  2015-10       Impact factor: 5.075

Review 6.  CNS complications of breast cancer: current and emerging treatment options.

Authors:  Evert C A Kaal; Charles J Vecht
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

7.  Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.

Authors:  Mohamed Ismail Nounou; Chris E Adkins; Evelina Rubinchik; Tori B Terrell-Hall; Mohamed Afroz; Tim Vitalis; Reinhard Gabathuler; Mei Mei Tian; Paul R Lockman
Journal:  Pharm Res       Date:  2016-08-15       Impact factor: 4.200

8.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment.

Authors:  Ticiana Leal; Julie E Chang; Minesh Mehta; H Ian Robins
Journal:  Curr Cancer Ther Rev       Date:  2011-11

9.  Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

Authors:  Brunilde Gril; Diane Palmieri; Julie L Bronder; Jeanne M Herring; Eleazar Vega-Valle; Lionel Feigenbaum; David J Liewehr; Seth M Steinberg; Maria J Merino; Stephen D Rubin; Patricia S Steeg
Journal:  J Natl Cancer Inst       Date:  2008-07-29       Impact factor: 13.506

10.  Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.

Authors:  B C Pestalozzi; P Francis; E Quinaux; S Dolci; E Azambuja; R D Gelber; G Viale; A Balil; M Andersson; B Nordenskjöld; M Gnant; J Gutierrez; I Láng; J P A Crown; M Piccart-Gebhart
Journal:  Ann Oncol       Date:  2008-06-18       Impact factor: 32.976
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.